Amifampridine SERB

What Is Amifampridine SERB and What Is It Used For?

Amifampridine SERB contains the active substance amifampridine (also known as 3,4-diaminopyridine or 3,4-DAP), formulated as amifampridine phosphate. It is the primary pharmacological treatment approved in the European Union for Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune condition classified as an orphan disease. LEMS affects approximately 3 to 4 people per million worldwide, making it one of the rarest neuromuscular disorders encountered in clinical practice.

Lambert-Eaton Myasthenic Syndrome is a disorder of neuromuscular transmission in which the body's immune system produces antibodies that attack voltage-gated calcium channels (VGCCs) on the presynaptic nerve terminal at the neuromuscular junction. Under normal circumstances, when a nerve impulse reaches the nerve ending, calcium flows into the terminal through these channels, triggering the release of acetylcholine — the chemical messenger responsible for transmitting the nerve signal to the muscle. In LEMS, the destruction of these calcium channels means that less calcium enters the nerve terminal, resulting in significantly reduced acetylcholine release. The muscle therefore receives insufficient nerve stimulation, leading to weakness.

LEMS may occur in two distinct clinical forms. In approximately 50-60% of cases, LEMS is associated with an underlying malignancy, most commonly small-cell lung cancer (SCLC), and is referred to as the paraneoplastic form. In these patients, the cancer cells express VGCCs, and the immune response originally directed against the tumor cross-reacts with the same channels at the neuromuscular junction. In the remaining 40-50% of cases, no cancer is identified, and the condition is termed the non-paraneoplastic (autoimmune) form of LEMS. This autoimmune variant tends to occur at a younger age and is often associated with other autoimmune diseases.

Amifampridine works by blocking voltage-gated potassium channels at the presynaptic nerve terminal. By inhibiting the outward flow of potassium ions, amifampridine prolongs the duration of the action potential at the nerve ending. This extended depolarization allows more calcium to flow into the terminal through the remaining functional calcium channels, thereby increasing the release of acetylcholine into the synaptic cleft. The enhanced acetylcholine release improves neuromuscular transmission and partially compensates for the deficit caused by the autoimmune attack on calcium channels, resulting in measurable improvement in muscle strength and function.

Clinical trials have demonstrated that amifampridine produces significant improvements in quantitative measures of muscle strength (QMG scores) and in patient-reported functional outcomes. A Cochrane systematic review confirmed the efficacy of 3,4-diaminopyridine in LEMS, showing statistically significant improvements in muscle strength scores and compound muscle action potential (CMAP) amplitudes compared to placebo. Most patients experience noticeable improvement in proximal limb weakness, the hallmark symptom of LEMS, as well as improvement in autonomic dysfunction symptoms such as dry mouth and constipation.

What Should You Know Before Taking Amifampridine SERB?

Before initiating treatment with Amifampridine SERB, a thorough medical evaluation is essential. Your prescribing physician will assess your complete medical history, current medications, and overall health status to determine whether this medication is appropriate for you. Because LEMS is a rare condition, treatment should be supervised by a specialist with experience in neuromuscular disorders.

Contraindications

The contraindication regarding QT-prolonging drugs is particularly important because amifampridine itself can affect cardiac electrical activity. Combining it with other QT-prolonging agents could potentially lead to dangerous cardiac arrhythmias, including torsades de pointes, a life-threatening ventricular tachycardia. Your doctor should review all of your current medications before prescribing amifampridine to ensure there are no dangerous interactions.

Warnings and Precautions

Inform your doctor before starting Amifampridine SERB if you have any of the following conditions:

• Asthma (even if controlled): Amifampridine may trigger bronchospasm and potentially precipitate asthma attacks. If you have a history of asthma, your doctor will carefully weigh the benefits against the risks.
• History of seizures (convulsions): Amifampridine can lower the seizure threshold. Patients with a history of epilepsy or seizure disorders should not take this medication. Even patients without a seizure history should be aware that seizures can occur, particularly at higher doses.
• Kidney problems: Amifampridine is partially excreted by the kidneys. Impaired renal function may lead to higher blood levels and increased risk of adverse effects. Dose adjustments are required for patients with moderate or severe kidney disease.
• Liver problems: Hepatic impairment can also affect the metabolism and clearance of amifampridine, necessitating dose modifications and closer monitoring.

Your doctor will perform cardiac monitoring (electrocardiogram) at the initiation of treatment and at least once a year thereafter. This is to check for any effects on the heart's electrical conduction system, particularly QT interval prolongation. If you experience palpitations, irregular heartbeat, fainting, or dizziness, report these symptoms immediately.

For patients with non-paraneoplastic LEMS (i.e. not associated with cancer), your doctor will perform a thorough evaluation to assess the potential risk of developing cancer before starting treatment. This is because LEMS can sometimes precede the diagnosis of an underlying malignancy, typically small-cell lung cancer, by several months or even years. Regular cancer screening is recommended, particularly during the first few years after LEMS diagnosis.

Always inform every healthcare provider you consult that you are taking Amifampridine SERB, including dentists, surgeons, and emergency physicians. This is especially important before any surgical procedure, as amifampridine may interact with certain anesthetic agents and muscle relaxants.

Pregnancy and Breastfeeding

Driving and Operating Machinery

Amifampridine SERB can cause drowsiness, dizziness, seizures, and blurred vision, all of which may impair your ability to drive or operate machinery safely. Do not drive or use machines if you experience any of these side effects. The underlying condition (LEMS) itself may also affect your ability to perform tasks requiring muscle strength and coordination. Discuss your individual risk with your doctor before resuming driving.

How Does Amifampridine SERB Interact with Other Drugs?

Drug interactions with Amifampridine SERB can be clinically significant and potentially dangerous. Because amifampridine affects potassium channels and can influence cardiac electrical activity, particular caution is needed when combining it with other medications. Your prescribing physician should review your complete medication list, including over-the-counter drugs, herbal supplements, and vitamins, before starting treatment. Never start, stop, or change the dose of any medication without consulting your doctor first.

Contraindicated Combinations (Must Not Be Used Together)

The following medications must never be taken at the same time as Amifampridine SERB due to the risk of potentially fatal cardiac arrhythmias caused by QT interval prolongation:

Important Interactions Requiring Caution

The following medications require special caution and close medical supervision if used concomitantly with Amifampridine SERB. Your doctor may need to adjust doses, increase monitoring frequency, or consider alternative treatments:

The interaction with muscle relaxants is particularly important in surgical settings. Patients with LEMS are inherently sensitive to neuromuscular blocking agents, and the combination with amifampridine can produce unpredictable responses. Your anesthesiologist must be informed that you are taking amifampridine before any surgical procedure. Depolarizing agents such as suxamethonium and non-depolarizing agents such as mivacurium may have prolonged or enhanced effects in LEMS patients.

Additionally, any drug that lowers the seizure threshold should be used with extreme caution in patients taking amifampridine, as the combination may increase the risk of convulsions. This is particularly relevant for tramadol, certain antidepressants (especially bupropion and tricyclics), and some antipsychotic medications.

What Is the Correct Dosage of Amifampridine SERB?

Always take Amifampridine SERB exactly as prescribed by your doctor. The optimal dose varies between individuals and is determined based on the severity of your symptoms, your clinical response, tolerability of side effects, and certain genetic factors that influence how your body metabolizes the drug. Do not change your dose without consulting your doctor.

Adults

When the total daily dose exceeds 20 mg, it should be divided into two to four separate doses taken at evenly spaced intervals throughout the day. The tablets have a score line and can be split into two equal halves. Tablets should be swallowed with water and taken with food to reduce the likelihood of gastrointestinal side effects.

The titration process should be gradual and guided by your doctor's assessment. Most patients find their optimal dose somewhere between 30 mg and 60 mg per day, although some may achieve adequate symptom control at lower doses. Your doctor will base dose adjustments on both objective measures of muscle strength and your subjective experience of symptom improvement.

Patients with Kidney or Liver Problems

In patients with impaired kidney or liver function, the clearance of amifampridine may be reduced, leading to higher circulating drug levels and potentially increased side effects. The slower dose titration schedule allows the body more time to adjust, and more frequent monitoring of side effects and clinical response is warranted. Your doctor may also order periodic blood tests to assess kidney and liver function during treatment.

Children and Adolescents

Amifampridine SERB is approved for use in adults only. There are insufficient safety and efficacy data to support its use in children and adolescents under 18 years of age. LEMS is exceedingly rare in the pediatric population. If a child or adolescent is diagnosed with LEMS, treatment decisions should be made by a pediatric neurologist at a specialized center.

Missed Dose

If you forget to take a dose of Amifampridine SERB, do not take a double dose to make up for the missed one. Simply continue with your regular dosing schedule as prescribed by your doctor. Taking a double dose increases the risk of side effects, including seizures and cardiac effects.

Overdose

Stopping Treatment

Do not stop taking Amifampridine SERB without consulting your doctor. If treatment is discontinued, you may experience a return of LEMS symptoms, including fatigue, slow reflexes, muscle weakness, and constipation. These symptoms can return relatively quickly as the beneficial effect of amifampridine wears off. If discontinuation is necessary, your doctor may recommend a gradual dose reduction rather than an abrupt stop.

What Are the Side Effects of Amifampridine SERB?

Like all medicines, Amifampridine SERB can cause side effects, although not everybody gets them. The intensity and frequency of most side effects are dose-dependent, meaning they tend to be more pronounced at higher doses. Many patients find that side effects diminish over time as the body adjusts to the medication. If side effects become bothersome, your doctor may be able to reduce your dose or adjust the dosing schedule.

The paraesthesia (tingling and numbness) is the most frequently reported side effect and is a direct pharmacological consequence of potassium channel blockade. It typically affects the perioral region (around the mouth) and the distal extremities (fingertips and toes). Most patients report that this sensation is mild to moderate and tends to diminish with continued treatment. If paraesthesia becomes severe or persistent, a dose reduction may be warranted.

Raynaud's phenomenon has been reported in some patients, presenting as episodes of reduced blood flow to the fingers or toes, causing them to turn white or blue and feel cold or numb. This is typically triggered by cold exposure or emotional stress. If you notice these symptoms, inform your doctor, as this may require treatment modifications or additional symptomatic management.

The cardiac side effects, including arrhythmias and palpitations, underscore the importance of cardiac monitoring before and during treatment. Patients should report any new-onset palpitations, chest pain, shortness of breath, or fainting episodes to their doctor promptly. Your doctor will likely request periodic electrocardiograms to monitor your heart rhythm.

How Should You Store Amifampridine SERB?

Proper storage of medications is essential to maintain their safety, efficacy, and quality. Amifampridine SERB should be stored under the following conditions:

• Keep out of sight and reach of children: Store the medication in a secure location where children cannot access it. Accidental ingestion by a child could be dangerous.
• Expiry date: Do not use this medicine after the expiry date stated on the carton and blister pack after "EXP". The expiry date refers to the last day of that month.
• Temperature: No special temperature storage requirements. Standard room temperature is acceptable.
• Light protection: Store in the original packaging to protect from light. The aluminium-PVC/PVDC blister packs provide adequate light protection when tablets are kept in the original blister.
• Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment.

The tablets are supplied in perforated unit dose blisters (10 × 1 tablets per blister strip) in pack sizes of 90, 100, or 120 tablets. Not all pack sizes may be marketed in all countries. Each tablet is individually sealed, which helps maintain stability and allows convenient carrying of individual doses when needed.

What Does Amifampridine SERB Contain?

Understanding the full composition of your medication is important, particularly if you have known allergies to any pharmaceutical excipients. Amifampridine SERB tablets contain the following:

Tablet description: Amifampridine SERB tablets are white, round, flat on one side and scored on the other side. The score line allows the tablet to be divided into two equal halves of 5 mg each, facilitating the dose titration process. This is particularly useful during the initial dose escalation phase and for patients who require fine dose adjustments.

The active substance, amifampridine (also known as 3,4-diaminopyridine), is formulated as the phosphate salt for improved stability and bioavailability. Amifampridine phosphate is more stable at room temperature compared to the free base form, which requires cold-chain storage. This formulation improvement was a key development that made the practical clinical use of amifampridine more feasible.

Amifampridine SERB contains the same active substance as the reference medicine Firdapse, which was the first amifampridine product authorized in the EU. Both products work in the same way and have comparable clinical efficacy. Firdapse was approved under "exceptional circumstances" by the European Medicines Agency (EMA), reflecting the rarity of LEMS and the inherent difficulty in conducting large-scale clinical trials in such a small patient population. The EMA reviews any new information annually and updates the product information accordingly.